Skip to main content
. 2023 Apr 13;33(8):5828–5839. doi: 10.1007/s00330-023-09605-0

Table 4.

Univariable and multivariable regression analysis assessing the correlation among clinical and radiological factors with prostate cancer

OUTCOME 1 Evidence of Tumor
n (%) – 389
p* ODDS RATIO* p** ODDS ratio**
Not Yes
Age (mean)  < 0.001 0.31 (0.21–0.40)  < 0.001 0.14 (0.06–0.22)
 < 70 148 87
 ≥ 70 49 105
Family history 0.41 0.63 (1.20–1.97)
NO 189 187
YES 8 5
PSA (ng/mL)
 < 10 159 135 0.02 0.57 (0.35–0.91) 0.46 0.04 (0.01–0.41)
 > 10, < 20 36 41 0.48 1.21 (0.74–2.00)
 > 20 2 16  < 0.001 0.17 (0.03–0.34) 0.51 0.12 (0.02–0.31)
PSA density (ng/mL2)  < 0.001 0.35 (0.25–0.43) 0.03 0.10 (0.09–0.11)
 < 0.15 150 81
 ≥ 0.15 47 111
Number of foci (n) 0.24 0.07 (0.03–0.16)
 1 98 83
 > 1 99 109
Best sequence  < 0.001 0.55 (0.46–0.63)  < 0.001 0.22 (0.13–0.32)
 DCE 148 38
 DWI/ADC 49 154
 Conventional PI-RADS score §  < 0.001 0.65 (0.56–0.74) 0.007 0.17 (0.05–0.30)
 Adjusted PI-RADS score §§  < 0.001 0.66 (0.59–0.74)  < 0.001 0.32 (0.19–0.45)

* Univariate analysis; p value < 0.05 was considered for statistical significance (bold values within the table)

** Multivariable analysis; p value < 0.05 was considered for statistical significance (bold values within the table)

§ PI-RADS with the conventional threshold to auction biopsy (PI-RADS 3 associated with PSA density ≥ 0.15 ng/mL/mL) assigned by an expert reader

§§ PI-RADS with the adjusted threshold to auction biopsy (both PI-RADS 3 and 3up associated with PSA density ≥ 0.15 ng/mL/mL) assigned by an expert reader

PSA, prostate-specific antigen; PI-RADS, Prostate Imaging—Reporting and Data System